Nigeria Launches Long-Acting HIV Prevention Injection, Lenacapavir, to Combat Epidemic
Nigeria has taken a significant step in its fight against HIV by introducing Lenacapavir, a new long-acting injectable medication for HIV prevention. This innovative treatment, administered every six months, offers a crucial alternative to daily oral pills, particularly for individuals who face challenges with adherence, stigma, or access to daily medication. The Federal Ministry of Health and Social Welfare launched the intervention with support from key international partners including the World Health Organization (WHO), the Global Fund, and the United States President's Emergency Plan for AIDS Relief (PEPFAR).
The rollout of Lenacapavir aligns with Nigeria's national priorities aimed at reducing new HIV infections and strengthening the country's response to the epidemic, which affects an estimated 1.9 million people. The drug is currently being introduced in pilot states, including Lagos, Kano, Benue, Anambra, Ebonyi, Gombe, Kwara, Akwa Ibom, Cross River, and the Federal Capital Territory (FCT), with an official nationwide launch anticipated. Authorities have stated that over 11,000 doses have already been delivered, with a planned total of 52,000 doses for the initial phase.
While the introduction of Lenacapavir has been widely welcomed by health professionals and public health advocates, there are important considerations and clarifications regarding its use. Medical experts emphasize that Lenacapavir is strictly a preventive measure for HIV-negative individuals and does not treat existing infections, nor does it protect against other sexually transmitted infections or unintended pregnancies. Additionally, due to insufficient safety data during pregnancy, it is currently not recommended for pregnant women.
Concerns have been raised by some organizations about potential misunderstandings among the public, with a belief that the injection could be a cure for HIV rather than a preventative tool. Health workers and officials are working to ensure clear communication about the drug's purpose and proper usage.
The introduction of Lenacapavir is part of a broader strategic shift in Nigeria's HIV response, as outlined in the new National HIV Prevention Plan for 2026–2030. This plan emphasizes a move from a treatment-focused approach to a more proactive, prevention-centric strategy that incorporates behavioral change and multi-sectoral collaboration. This comprehensive approach aims to address the persistent gaps in HIV prevention and accelerate progress towards the goal of ending AIDS as a public health threat by 2030.
The rollout of Lenacapavir aligns with Nigeria's national priorities aimed at reducing new HIV infections and strengthening the country's response to the epidemic, which affects an estimated 1.9 million people. The drug is currently being introduced in pilot states, including Lagos, Kano, Benue, Anambra, Ebonyi, Gombe, Kwara, Akwa Ibom, Cross River, and the Federal Capital Territory (FCT), with an official nationwide launch anticipated. Authorities have stated that over 11,000 doses have already been delivered, with a planned total of 52,000 doses for the initial phase.
While the introduction of Lenacapavir has been widely welcomed by health professionals and public health advocates, there are important considerations and clarifications regarding its use. Medical experts emphasize that Lenacapavir is strictly a preventive measure for HIV-negative individuals and does not treat existing infections, nor does it protect against other sexually transmitted infections or unintended pregnancies. Additionally, due to insufficient safety data during pregnancy, it is currently not recommended for pregnant women.
Concerns have been raised by some organizations about potential misunderstandings among the public, with a belief that the injection could be a cure for HIV rather than a preventative tool. Health workers and officials are working to ensure clear communication about the drug's purpose and proper usage.
The introduction of Lenacapavir is part of a broader strategic shift in Nigeria's HIV response, as outlined in the new National HIV Prevention Plan for 2026–2030. This plan emphasizes a move from a treatment-focused approach to a more proactive, prevention-centric strategy that incorporates behavioral change and multi-sectoral collaboration. This comprehensive approach aims to address the persistent gaps in HIV prevention and accelerate progress towards the goal of ending AIDS as a public health threat by 2030.
This article and image are AI generated. For informational purposes only.